19 March 2024>: Original Paper
Long-Term Outcomes with Prolonged-Release Tacrolimus in Kidney Transplantation: A Retrospective Real-World Data Analysis
Wilfried Gwinner 1ABDE* , Swapneel Anaokar 2ACDE , Martin Blogg 2ACDE , Birgit Hermann 3ACDE , Carola del Pilar Repetur 2CDE , Mario Schiffer 4ABDEDOI: 10.12659/AOT.942167
Ann Transplant 2024; 29:e942167
Table 2 Patient demographics per transplant center.
Parameter | Center 1 (n=81) | Center 2 (n=82) | P value |
---|---|---|---|
Age, mean (SD) | 54.6 (12.3) | 46.6 (13.7) | |
Age ≥65 years, n (%) | 20 (24.7) | 8 (9.8) | 0.011 |
Male, n (%) | 62 (76.5) | 55 (67.1) | 0.179 |
Living donor, n (%) | 20 (24.7) | 35 (42.7) | 0.015 |
ECD status, n (%) | 36 (44.4) | 9 (11.0) | |
Comorbidities at baseline (type 2 diabetes), n (%) | 18 (22.2) | 6 (7.3) | 0.007 |
CMV donor IgG positive/recipient IgG negative, n (%) | 25 (30.9) | 19 (23.2) | 0.269 |
CMV – cytomegalovirus; ECD – expanded criteria donor; IgG – immunoglobulin G; SD – standard deviation. Center 1, Universitäts-klinikum Erlangen; Center 2, Medizinische Hochschule Hannover. |